PharmaCyte Biotech, Inc.
PMCB
$1.04
$0.032.97%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -171.15% | 485.83% | -107.22% | -106.27% | 1,639.17% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 152.12% | -764.76% | 144.53% | 103.61% | -1,253.88% |
| Change in Net Operating Assets | -175.91% | 197.92% | 193.97% | -457.44% | 44.32% |
| Cash from Operations | -91.66% | -104.04% | 51.65% | -182.53% | -12.10% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Investing | -- | -- | -- | 100.00% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 23.78% | 83.97% | -89.10% | 36.81% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | 100.00% | 60.15% | 0.98% | 0.97% |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 95.65% | 63.26% | -5.59% | 4.91% |
| Foreign Exchange rate Adjustments | -83.33% | 150.00% | -1,300.00% | -50.00% | 150.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -64.61% | 72.82% | 62.22% | 32.77% | -59.06% |